Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM-BCP-01
- Development stage
- Discontinued
- Lead developer
- Immunome
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**IMM-BCP-01** is an investigational, fixed-combination SARS-CoV-2 neutralizing antibody cocktail developed by Immunome for treatment of COVID-19. It contains three patient-derived human monoclonal antibodies—IMM20184, IMM20190, and IMM20253—that bind distinct, non-overlapping conserved epitopes on the SARS-CoV-2 spike glycoprotein. IMM20184 and IMM20190 inhibit spike interaction with the ACE2 receptor, while IMM20253 binds a cryptic receptor-binding-domain epitope and promotes spike-trimer disruption. The cocktail also induces Fc-mediated antiviral clearance mechanisms, including antibody-dependent cellular cytotoxicity, complement activation, and phagocytosis. It entered an intravenous Phase 1b study in mild to moderate COVID-19, but the study was terminated following Immunome's strategic decision to discontinue further internal development and seek a partner.
- Other names
- IMM20184, IMM20190, IMM20253 drug combinationIMM20184-IMM20190-IMM20253IMM-20184-IMM20190-IMM20253IMM 20184-IMM20190-IMM20253IMMBCP01IMMBCP-01IMMBCP 01
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on IMM-BCP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM-BCP-01.